PHAXIAM Therapeutics 관리

관리 기준 확인 2/4

PHAXIAM Therapeutics CEO는 Thibaut Fayet, Jun2023 에 임명되었습니다 의 임기는 1.42 년입니다. 총 연간 보상은 € 391.73K, 34.5% 로 구성됩니다. 34.5% 급여 및 65.5% 보너스(회사 주식 및 옵션 포함). 는 € 8.69K 가치에 해당하는 회사 주식의 0.055% 직접 소유합니다. 8.69K. 경영진과 이사회의 평균 재임 기간은 각각 1.4 년과 11.5 년입니다.

주요 정보

Thibaut Fayet

최고 경영자

€391.7k

총 보상

CEO 급여 비율	34.5%
CEO 임기	1.4yrs
CEO 소유권	0.05%
경영진 평균 재임 기간	1.4yrs
이사회 평균 재임 기간	11.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Thibaut Fayet 의 보수는 PHAXIAM Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-€22m
Mar 31 2024	n/a	n/a	-€23m
Dec 31 2023	€392k	€135k	-€23m

보상 대 시장: Thibaut 의 총 보상 ($USD 414.52K )은 German 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 475.63K ).

보상과 수익: Thibaut 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Thibaut Fayet (56 yo)

1.4yrs

테뉴어

€391,725

보상

Mr. Thibaut du Fayet serves as Chief Executive Officer at PHAXIAM Therapeutics S.A. since June 23, 2023. He served as Chief Operating Officer and served as Member of the Executive Board at Pherecydes Pharm...

리더십 팀

이름	위치	테뉴어	보상	소유권
Thibaut Fayet	Chief Executive Officer	1.4yrs	€391.73k	0.055% € 8.7k
Jérôme Bailly	Deputy CEO	4.8yrs	€262.41k	0.0038% € 599.6
Frédéric Mathat	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Cindy Fevre	Chief Scientific Officer	1.8yrs	데이터 없음	데이터 없음
Naomi Eichenbaum	Director Investor Relations	no data	데이터 없음	데이터 없음
Pascal Birman	Chief Medical Officer	1.4yrs	데이터 없음	데이터 없음
Philip Lorenzi	Consultant & Member of Scientific Board	no data	데이터 없음	데이터 없음
Eric Raymond	Consultant & Member of Scientific Board	no data	데이터 없음	데이터 없음
Bridget Bax	Consultant & Member of Scientific Board	no data	데이터 없음	데이터 없음
Arthur Frankel	Consultant & Member of Scientific Board	no data	데이터 없음	데이터 없음
Kurt Gunter	Consultant & Member of Scientific Board	no data	데이터 없음	데이터 없음

1.4yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: 2E40 의 관리팀은 경험 (평균 재직 기간 1.4 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Philip Lorenzi	Consultant & Member of Scientific Board	14.8yrs	데이터 없음	데이터 없음
Eric Raymond	Consultant & Member of Scientific Board	15.1yrs	데이터 없음	데이터 없음
Bridget Bax	Consultant & Member of Scientific Board	12.8yrs	데이터 없음	데이터 없음
Arthur Frankel	Consultant & Member of Scientific Board	12.8yrs	데이터 없음	데이터 없음
Kurt Gunter	Consultant & Member of Scientific Board	12.8yrs	데이터 없음	데이터 없음
Philippe Archinard	Independent Director	11.5yrs	€68.00k	0.010% € 1.6k
Gil Beyen	Vice Chairman	11.5yrs	€1.00m	0.0048% € 766.1
Hilde Windels	Independent Director	10.2yrs	€56.75k	데이터 없음
Didier Hoch	Chairman of the Board	1.4yrs	€153.18k	데이터 없음
Leila Nicolas	Representative Director	1.4yrs	€26.25k	데이터 없음
Robert Sebbag	Independent Director	1.4yrs	€21.75k	데이터 없음
Valerie Faillat	Independent Director	less than a year	데이터 없음	데이터 없음

11.5yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: 2E40 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.5 년).

PHAXIAM Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

Recent updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

New 90-day low: €6.90

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

New 90-day high: €8.81

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

New 90-day high: €7.70

New 90-day high: €6.33

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

New 90-day low: €4.30

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

New 90-day low: €4.82

New 90-day low - €6.02

New 90-day low - €6.62

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령